- Home
- ECOR vs ELUT Comparison
ECOR vs ELUT Comparison
Compare ECOR & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ECOR | ELUT |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1M | 48.3M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ECOR | ELUT |
|---|---|---|
| Price | $7.16 | $0.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $18.00 | $6.00 |
| AVG Volume (30 Days) | 52.1K | ★ 72.4K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.77 |
| EPS | N/A | ★ 0.87 |
| Revenue | ★ $32,032,000.00 | $12,293,000.00 |
| Revenue This Year | $33.60 | N/A |
| Revenue Next Year | $30.40 | $10.83 |
| P/E Ratio | ★ N/A | $1.16 |
| Revenue Growth | ★ 27.20 | N/A |
| 52 Week Low | $4.16 | $0.50 |
| 52 Week High | $8.30 | $2.60 |
Technical Indicators
Market Signals| Indicator | ECOR | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 61.91 | 37.07 |
| Support Level | $4.55 | $0.86 |
| Resistance Level | $7.50 | $0.99 |
| Average True Range (ATR) | 0.48 | 0.06 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 82.55 | 11.99 |
Price Performance
Historical ComparisonAbout ECOR electroCore Inc.
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.
About ELUT Elutia Inc.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.